Manufacturer record
Primus Pharmaceuticals: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
8 batches manufactured by Primus Pharmaceuticals (Himachal Pradesh) were declared Not of Standard Quality between May 2021 and February 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
8 records linked to Primus Pharmaceuticals in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Amoxycillin & Potassium Clavulanate Injection IP 1.2 gm | PD052505AMfg 2025-05 · Exp 2027-04 | The sample received does not conform to I.P. 2022 specification with respect to the Assay for the content of potassium clavulanate equivalent to clavulanic acid only.Assay | CDTL, HyderabadCDSCO lab | Feb 2026 |
| Pregabalin & Nortriptyline Tablets | PT-042515Mfg 2025-04 · Exp 2027-03 | The sample does not conform to the claim with respect to Assay in Nortriptyline.Assay | DTL JaipurState lab | Jan 2026 |
| Ibuprofen Suspension 100mg/5ml | PL-022502Mfg 2025-02 · Exp 2027-01 | Test for pHpH | DTL, Bengaluru, KarnatakaState lab | Jan 2026 |
| Hyoscine Butylbromide Tablets IP (BUSCOPRIME -10 TABLETS) | PT-102441Mfg 2024-10 · Exp 2026-09 | Assay of Hyoscine ButylbromideAssay | RDTL ChandigarhCDSCO lab | Jan 2025 |
| Natamycin Ophthalmic Suspension IP (Nataprime Eye Drops) | PE062308Mfg 2023-06 · Exp 2025-05 | SterilitySterility | CDL KolkataCDSCO lab | Oct 2024 |
| Gentamicin Sulphate Injection IP (P- Genta Injection) | PA022415Mfg 2024-02 · Exp 2026-01 | pHpH | CDTL MumbaiCDSCO lab | Sep 2024 |
| Cefoperazone Injection IP. (NOZACEF-1 GM) | PD042309Mfg 2023-04 · Exp 2025-03 | Assay of CefoperazoneAssay | RDTL GuwahatiState lab | Dec 2023 |
| Inmecin R (Indomethacin Sustained Release Capsules U.S.P.) | PC-111958Mfg 2019-11 · Exp 2022-04 | DissolutionDissolution | CDL KolkataCDSCO lab | May 2021 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.